Jud Hamblin recently visited Bristol-Myers Squibb, one of the leading pharmaceutical companies pioneering new immunotherapy treatments to fight cancer.  During his visit he took part in a staff meeting where he was able to share his kidney cancer journey, from diagnosis to treatment, to help employees better understand a patients’ perspectives on the disease and its treatment. Jud is pictured with (l-r) Giovanni Caforio (BMS CEO), Ben Hickey (General Manager BMS UK & Ireland) and Johanna Mercier (BMS Head of Worldwide Markets).
 
KCSN partners with the pharmaceutical industry, research institutes, hospitals and clinics to improve understanding of the kidney cancer patient journey and to highlight the various issues faced by patients during their care and treatment. Our goal is that this collaborative approach between patients and professionals will eventually lead to a more patient-centred approach to the care and treatment pathway for kidney cancer, so that patients become more involved in shared decisions about their treatment options. Please contact Rose or Julia for support, information or a friendly person to chat to on our confidential helpline 01209 890326, or join our closed FaceBook group to meet and chat with other kidney cancer patients and carers.

Share this Post!

  TOP